Список проголосовавших за комментарий " On The Wires<ul><li>GenomeDx Biosciences announced that it has entered into a research collaboration with Astellas (<strong>ALPMY</strong>) to apply genomic tumor profiling using GenomeDx's Decipher Classifier and Decipher GRID as a potential aid in the identification of prostate cancer patients undergoing active surveillance who may benefit from treatment with XTANDI (enzalutamide). As part of the agreement, Astellas will provide GenomeDx with tumor samples from its Phase 2 ENACT trial (NCT02799475), which is comparing the time to prostate cancer progression between patients treated with enzalutamide versus patients undergoing active surveillance.</li><li>CB&I (<strong>CBI</strong>) announced it has been awarded a contract by Shaanxi Yanchang Petrochemical Group for the license and engineering design of an alkylation unit in Yan'an City, Shaanxi, China. The alkylation unit will use CB&I's CDAlky advanced sulfuric acid alkylation technology.</li><li>Salesforce (<strong>CRM</strong>) announced that the U.S. Department of Agriculture Farm Service Agency will use Salesforce Service Cloud to power a new program for FSA customers known as «Bridges to Opportunity.» The program is designed to provide farmers and ranchers with information on non-USDA programs that will benefit and grow their operations, ultimately helping them meet their goals.</li><li>On January 31, 2017, Symantec (<strong>SYMC</strong>) informed LifeLock (<strong>LOCK</strong>) that it had not completed its debt financing and, in accordance with the terms of the Amendment, Symantec was electing to extend the Closing. LifeLock currently expects that the Merger will be completed on February 9, 2017.</li></ul>"